Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals

Clinical and Experimental Immunology

Volumn 121, Issue 3, 2000, Pages 515-522

  Odaka, C ^a   Mizuochi, T ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Angiotensin converting enzyme; Apoptosis; Captopril; T cell activation

Indexed keywords

CAPTOPRIL; CASPASE 3; CD3 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FAS ANTIGEN; INTERLEUKIN 2;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNITY; CAPTOPRIL; CASPASE 3; CASPASES; FAS LIGAND PROTEIN; HUMANS; HYBRIDOMAS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0033850883     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01323.x     Document Type: Article

References (61)

1. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids
2. Captopril: Pharmacology, metabolism and disposition
3. Angiotensin converting inhibitors in rheumatoid arthritis
4. Captopril: A new treatment for rheumatoid arthritis?
5. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
6. Effect of SQ 14225, an inhibitor of angiotensin I-converting enzyme, on the granulomatous response to Schistosoma mansoni eggs in mice
7. Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL 1pr/1pr mice
8. Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis
9. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells
10. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo
11. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells
12. Influence of angiotensin converting enzyme inhibitor (captopril) on kidney epithelial cells in vitro: Studies on potassium (86Rb) influx and cellular proliferation
13. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate
14. Captopril inhibits proliferation of human lung fibroblasts in culture: A potential antifibrotic mechanism
15. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture
16. Copper chelates of antirheumatic and anti-inflammatory agents: Their superoxide dismutase-like activity and stability
17. Superoxide dismutase activity of the captopril-iron complex
18. Captopril and glutathione inhibit the superoxide dismutase activity of Hg (II)
19. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases
20. Captopril inhibits glioma cell invasion in vitro: Involvement of matrix metalloproteinases
21. Immunosuppressive action of captopril blocked by prostaglandin synthetase inhibitor
22. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors
23. PGE2 production after angiotensin-converting enzyme inhibition
24. Radiation-induced pulmonary endothelial dysfunction in rats: Modification by an inhibitor of angiotensin converting enzyme
25. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells
26. Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells
27. Captopril inhibits apoptosis in human lung epithelial cells: A potential antifibrotic mechanism
28. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes
29. Activation-driven T cell death I. Requirements for de novo transcription and translation and association with genome fragmentation
30. T cell receptor-mediated DNA fragmentation and cell death in T cell hybridomas
31. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
32. Autocrine T-cell suicide mediated by APO-1/ (Fas/CD95)
33. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation
34. Quantitation of DNA fragmentation using fiberglass filters
35. The JAM test. A simple assay for DNA fragmentation and cell death
36. 9-cis-retinoic Acid inhibits activation-driven T-cell apoptosis: Implications for retinoid X receptor involvement in thymocyte development
37. Human ICE/CED-3 protease nomenclature
38. Caspases: Enemies within
39. Specific activation of the cysteine protease CPP32 during the negative selection of T cells in the thymus
40. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
41. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis
42. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification
43. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents
44. A new class of angiotensin-converting enzyme inhibitors
45. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
46. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats
47. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma
48. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506
49. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: One in the presence and one in the absence of CsA
50. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
51. Transcriptional regulation of the human FasL promoter-enhancer region
52. Angiotensin I-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes
53. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors
54. Inhibition of dopamine beta hydroxylase by captopril
55. Inhibition of leukotriene A4 hydrolase/aminopeptidase by captopril
56. Drug-induced systemic lupus erythematosus. Differentiating it from the real thing
57. Drug-associated glomerulopathies
58. Lupus erythematosus-like eruption from captopril
59. Captopril and systemic lupus erythematosus syndrome
60. Drug-induced lupus-like reaction and captopril
61. Captopril-induced lupus